Premium
Bevacizumab for NF2‐associated vestibular schwannomas of childhood and adolescence
Author(s) -
Renzi Samuele,
Michaeli Orli,
Salvador Hector,
Alderete Daniel,
Ponce Nicolas Fernandez,
Zapotocky Michal,
Hansford Jordan R.,
Malalasekera Vajiranee S.,
Toledano Helen,
Maguire Bryan,
Bouffet Eric,
Ramaswamy Vijay,
Baroni Lorena V.
Publication year - 2020
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28228
Subject(s) - medicine , neurofibromatosis type 2 , bevacizumab , hearing loss , vestibular schwannomas , vestibular system , pediatrics , audiology , surgery , chemotherapy , schwannoma
Seventeen children at six institutions with neurofibromatosis type 2 (NF2)‐related vestibular schwannomas received bevacizumab. Eight of the 13 patients with initial hearing loss (61%) showed objective hearing improvement within six months of treatment. No patients showed hearing deterioration during therapy; however, only two patients showed objective radiological response. Seven of eight patients had tumor progression or worsening hearing loss upon cessation of treatment. Bevacizumab was well tolerated with no patients discontinuing therapy. Bevacizumab appears to postpone hearing loss in childhood NF2‐associated vestibular schwannomas, but responses are not durable, suggesting that either longer maintenance therapy or new strategies are required.